US Patent

US8226929 — Contrast agents for myocardial perfusion imaging

Method of Use · Assigned to Lantheus Medical Imaging Inc · Expires 2028-06-21 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for imaging myocardial perfusion using a contrast agent that binds MC-1 and includes an imaging moiety.

USPTO Abstract

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4011`	—

Patent Metadata

Patent number: US8226929
Jurisdiction: US
Classification: Method of Use
Expires: 2028-06-21
Drug substance claim: No
Drug product claim: No
Assignee: Lantheus Medical Imaging Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.